Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF ACCRUED EXPENSES (Details)

v3.22.1
SCHEDULE OF ACCRUED EXPENSES (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Accrued clinical operations and trials costs $ 2,132,865 $ 5,435,464
Accrued product development costs 7,788 203,676
Accrued compensation 1,549,871 2,715,368
Accrued administrative costs 1,198,396 1,213,699
Accrued interest 607,486 525,105
Total $ 5,496,406 $ 10,093,312